insulin resistance overweight
Conditions
Interventions
The subjects will be divided in 2 intervention groups:
1. 1. GOS: Domo® Vivinal® galacto-oligosaccharide rich whey product
5g 3x per day (269.6kjoule/day)
2. Placebo: Maltodextrin
5.65g 3xper day (2
Sponsors
Universiteit Maastricht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Overweight/obese (BMI * 28 kg/m2
Exclusion criteria
Exclusion criteria: Subjects will be excluded from participation when one or more of the following aspects are present: - diabetes mellitus - gastroenterological diseases or major abdominal surgery (allowed i.e.: appendectomy, cholecystectomy) - lactose intolerance and other digestive disorders - cardiovascular disease, cancer, liver or kidney malfunction (determined based on ALAT and creatinine levels, respectively) - disease with a life expectancy shorter than 5 years - abuse of products (alcohol consumption > 15 units/week, or any drugs) - excessive nicotine use defined as >20 cigarettes per day - plans to lose weight or follow a hypocaloric diet - regular supplement of pre- or probiotic products - intensive exercise more than three hours a week - - use of any medication that influences glucose or fat metabolism and inflammation, like i.e. *-blockers, lipid lowering-drugs (e.g. PPAR * or PPAR* (fibrates) agonists), glucose-lowering agents (including all sulfonylureas, biguanides, *-glucosidase inhibitors, thiazolidinediones, repaglinide, nateglinide and insulin), anti-oxidants or chronic corticosteroids treatment. - use of laxation products in the last three months or during the study period;- use of antibiotics in the last three months or during the study period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary endpoint: whole-body insulin sensitivity as assessed by a one-step hyperinsulinemic euglycemic clamp | — |
Secondary
| Measure | Time frame |
|---|---|
| - energy expenditure and substrate oxidation (indirect calorimetry) - adipose tissue and skeletal muscle gene/protein expression - faecal and circulating SCFA - faecal microbiota composition - circulating incretins, metabolites and inflammatory parameters - body weight, BMI and body composition (DEXA scan) - volatile organic compounds (VOCs) in exhaled air | — |
Countries
Netherlands
Outcome results
None listed